commitment
to biosimiliars

Every biosimilar we add to our portfolio
provides more patients in more
countries with the treatment they need.
We are committed to continuing to
invest in biosimilars.

Diabetes &
Metabolics

Oncology

Dermatology

Immunology

Ophthalmology

growing portfolio

We offer one of the industry's largest and most diverse global biosimilars franchises focused on the areas of oncology, immunology, endocrinology, ophthalmology and dermatology.

industry-wide savings

  • Biosimilars play an important role in our commitment by offering additional therapeutic options to more expensive biologics.
  • It is projected that biosimilars will potentially generate a savings of $54 billion in direct spending on biologic drugs in the U.S. between 2017 and 2026.1

Reference:
1. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. (2017-2026). RAND Corporation, 2017.